By Mike Montemarano, Associate Editor06.17.22
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee has advanced a bill to reauthorize user fee agreements for drugs and medical devices that retains language on dietary supplements that industry trade groups had lobbied to remove or revamp.
The committee voted 13-9 to send the FDA Safety and Landmark Advancements Act (FDASLA) to the full Senate for consideration. Among other provisions, the legislation would mandate product listing of dietary supplements at the time of introduction into interstate commerce. It would also make it a “prohibited act” to introduce and market a product as a dietary supplement that authorities determine doesn’t meet the definition of a dietary supplement.
The Natural Products Association (NPA), which has encouraged industry stakeholders to voice their opposition to mandatory product listing (MPL), said the FDASLA would remove protections for dietary supplement manufacturers under the Bioterrorism Act and would all
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
